In addition, we previously found that Zyflamend, a multiherbal anti-inflammatory product (New Chapter) had a strong ability to downregulate both 12-LOX and 12-HETE and that this correlated with the product’s ability to inhibit proliferation of PC-3 prostate cancer cells (33). This evidence concerns the gene ALOX15 and prostate cancer.